Edition:
India

PDL BioPharma Inc (PDLI.OQ)

PDLI.OQ on NASDAQ Stock Exchange Global Select Market

2.92USD
14 Dec 2018
Change (% chg)

$-0.02 (-0.68%)
Prev Close
$2.94
Open
$2.93
Day's High
$2.99
Day's Low
$2.91
Volume
443,916
Avg. Vol
414,391
52-wk High
$3.16
52-wk Low
$2.25

Latest Key Developments (Source: Significant Developments)

Pdl Biopharma Q2 GAAP Loss Per Share $0.76
Thursday, 9 Aug 2018 

PDL BioPharma Inc ::PDL BIOPHARMA REPORTS SECOND QUARTER 2018 FINANCIAL RESULTS.Q2 REVENUE $46.6 MILLION VERSUS $143.8 MILLION.Q2 GAAP LOSS PER SHARE $0.76.HAD CASH, CASH EQUIVALENTS, SHORT-TERM INVESTMENTS AND OTHER INVESTMENTS OF $395.7 MILLION AS OF JUNE 30.  Full Article

PDL Biopharma Buys Depomed's Remaining Interest In Royalties, Milestones On T2 Diabetes Products
Friday, 3 Aug 2018 

Aug 2 (Reuters) - PDL BioPharma Inc ::PDL BIOPHARMA ACQUIRES DEPOMED'S REMAINING 50% INTEREST IN ROYALTIES AND MILESTONES ON TYPE 2 DIABETES PRODUCTS.UNDER TERMS OF AMENDMENT, PDL HAS MADE AN INITIAL PAYMENT OF $10 MILLION TO DEPOMED.AN ADDITIONAL $10 MILLION WILL BE PAYABLE IF DEPOMED MEETS CERTAIN CONDITIONS SPECIFIED IN AMENDMENT.EXPECT AMENDED TRANSACTION TO BEGIN YIELDING RETURNS TO PDL IN LATE 2020 AND TO PROVIDE MEANINGFUL CASH FLOW THROUGH 2026.EXPECT AMENDED TRANSACTION TO BEGIN YIELDING RETURNS TO PDL IN LATE 2020 AND TO PROVIDE MEANINGFUL CASH FLOW THROUGH 2026.  Full Article

NODEN PHARMA ANNOUNCES U.S. FDA APPROVAL OF TEKTURNA ORAL PELLETS
Wednesday, 15 Nov 2017 

Nov 15 (Reuters) - Noden Pharma DAC::NODEN PHARMA ANNOUNCES FDA APPROVAL OF TEKTURNA®(ALISKIREN) ORAL PELLETS FOR THE TREATMENT OF HYPERTENSION IN ADULTS AND CHILDREN 6 YEARS OF AGE AND OLDER.NODEN PHARMA DAC SAYS PLANS TO MAKE TEKTURNA ORAL PELLETS AVAILABLE IN 2018​.‍NODEN PHARMA DAC SAYS NEW FORMULATION AND PEDIATRIC INDICATION WERE APPROVED THROUGH FDA PRIORITY REVIEW PROCESS​.  Full Article

PDL Biopharma urges Neos Therapeutics to provide update on sale process
Wednesday, 8 Nov 2017 

Nov 8 (Reuters) - PDL Biopharma :PDL Biopharma's proposal to acquire Neos Therapeutics expires today; PDL urges Neos to provide update on sale process.Reiterated that its proposal to acquire Neos Therapeutics Inc for $10.25 per share in cash will expire today at market close​.Decided it will not extend deadline for, or otherwise alter, its proposal​.  Full Article

PDL Biopharma Inc reports Q3 revenue $62.7 million
Friday, 3 Nov 2017 

Nov 2 (Reuters) - PDL Biopharma Inc :PDL Biopharma Inc announces third quarter 2017 financial results.Q3 revenue $62.7 million.PDL Biopharma Inc - ‍qtrly GAAP diluted EPS of $0.14​.  Full Article

PDL Biopharma issues response to Neos Therapeutics rejection of PDL acquisition proposal
Tuesday, 31 Oct 2017 

Oct 30 (Reuters) - Pdl Biopharma Inc :PDL Biopharma issues statement in response to Neos Therapeutics rejection of PDL acquisition proposal.PDL Biopharma Inc - ‍PDL's proposal to Neos remains outstanding through November 8, 2017 & co will evaluate "all of its options" in interim​.  Full Article

PDL Biopharma announces settlement agreement with Valeant
Monday, 30 Oct 2017 

Oct 30 (Reuters) - PDL Biopharma Inc :PDL Biopharma announces settlement agreement with Valeant.PDL Biopharma - ‍Valeant to pay a one-time, lump-sum payment of $13.0 million as part of settlement.PDL Biopharma - ‍Valeant's one-time, lump-sum payment will be transferred to co pursuant to terms of Depomed royalty agreement.PDL Biopharma - ‍Valeant's one-time, lump-sum payment to co will not recognized as revenue by Depomed​.PDL - ‍depomed, co to release Valeant from claims against it arising from royalty audit, Valeant's obligation to pay royalties during audit period​.PDL Biopharma Inc- ‍valeant will release Depomed, co from all claims against them as a result of audit and/or litigation​.PDL - ‍entered into settlement with Valeant that resolves matters relating to "alleged underpayment of royalties by Valeant"​.  Full Article

Neos Therapeutics‍ confirms it got unsolicited proposal from PDL Biopharma
Thursday, 26 Oct 2017 

Oct 26 (Reuters) - Neos Therapeutics Inc ::Says confirmed it received unsolicited proposal from PDL Biopharma to buy co for $10.25 per share in cash​.Says Neos board will respond to PDL proposal received on Oct 26 in due course​.  Full Article

PDL BioPharma proposes to acquire Neos Therapeutics for $10.25 per share
Thursday, 26 Oct 2017 

Oct 26 (Reuters) - Pdl Biopharma Inc :PDL Biopharma proposes to acquire NEOS THERAPEUTICS for $10.25 per share in cash.PDL Biopharma Inc - ‍PDL proposal is not subject to any financing conditions​.PDL Biopharma Inc - ‍PDL proposal will remain outstanding for a period of fourteen days​.PDL BioPharma Inc - ‍on June 23, 2017, PDL formally proposed to acquire Neos for $10.25 per share, a proposal Neos Board promptly rejected​.PDL BioPharma Inc - ‍reconfirming proposal to purchase Neos Therapeutics for a cash purchase price of $10.25 per share​.PDL BioPharma Inc - ‍following Neos' dilutive financing at $6.25 per share, PDL maintained its $10.25 proposal to Board​.  Full Article